{"transactions":[{"id":2660,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":83690,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":75.78,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":83690},"source":{"system":"sec-edgar","filing":"0001140361-26-035613","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1983476/000114036126035613/form4.xml","form_type":"4"}},{"id":2659,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":124962,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":49.07,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":124962},"source":{"system":"sec-edgar","filing":"0001140361-26-035613","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1983476/000114036126035613/form4.xml","form_type":"4"}},{"id":2658,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":110665,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":110665},"source":{"system":"sec-edgar","filing":"0001140361-26-035613","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1983476/000114036126035613/form4.xml","form_type":"4"}},{"id":2657,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:39:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":167123,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035613","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1983476/000114036126035613/form4.xml","form_type":"4"}},{"id":2656,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:39:14.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1375,"price":135.06,"value":185707.5,"ownership":{"direct":true},"balance_after":167123,"source":{"system":"sec-edgar","filing":"0001140361-26-035613","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1983476/000114036126035613/form4.xml","form_type":"4"}},{"id":692680,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-08T00:00:09.000Z","date":"2026-08-05","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":110665,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-092838","document":"tm2622546-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926092838/tm2622546-1_4seq1.xml","form_type":"4"}},{"id":692679,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-08T00:00:09.000Z","date":"2026-08-05","kind":"sale","planned":true,"acquired":false,"shares":5500,"price":134.17,"value":737935.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."}],"balance_after":168498,"source":{"system":"sec-edgar","filing":"0001104659-26-092838","document":"tm2622546-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926092838/tm2622546-1_4seq1.xml","form_type":"4"}},{"id":692678,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-08T00:00:09.000Z","date":"2026-08-05","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":173998,"source":{"system":"sec-edgar","filing":"0001104659-26-092838","document":"tm2622546-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926092838/tm2622546-1_4seq1.xml","form_type":"4"}},{"id":707774,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-17T00:00:13.000Z","date":"2026-07-14","kind":"gift","planned":false,"acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund."}],"balance_after":169873,"source":{"system":"sec-edgar","filing":"0001104659-26-084344","document":"tm2620587-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926084344/tm2620587-1_4seq1.xml","form_type":"4"}},{"id":716926,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-03T00:13:06.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":114790,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-080477","document":"tm2619720-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926080477/tm2619720-1_4seq1.xml","form_type":"4"}},{"id":716925,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T00:13:06.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":5500,"price":132.74,"value":730070.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."}],"balance_after":177873,"source":{"system":"sec-edgar","filing":"0001104659-26-080477","document":"tm2619720-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926080477/tm2619720-1_4seq1.xml","form_type":"4"}},{"id":716924,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T00:13:06.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":183373,"source":{"system":"sec-edgar","filing":"0001104659-26-080477","document":"tm2619720-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926080477/tm2619720-1_4seq1.xml","form_type":"4"}},{"id":727216,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T00:01:46.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":26400,"price":132.6,"value":3500640.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.550 to $132.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":179248,"source":{"system":"sec-edgar","filing":"0001104659-26-077427","document":"tm2618514-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926077427/tm2618514-1_4seq1.xml","form_type":"4"}},{"id":740704,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T20:36:30.000Z","date":"2026-06-12","kind":"sale","planned":true,"acquired":false,"shares":12583,"price":70.109,"value":882181.547,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive."}],"balance_after":38743,"source":{"system":"sec-edgar","filing":"0000907654-26-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000054/form4.xml","form_type":"4"}},{"id":740703,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T20:36:30.000Z","date":"2026-06-11","kind":"sale","planned":true,"acquired":false,"shares":22417,"price":70.1343,"value":1572200.6031,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":51326,"source":{"system":"sec-edgar","filing":"0000907654-26-000054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000054/form4.xml","form_type":"4"}},{"id":747334,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-06T00:00:14.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":118915,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-071076","document":"tm2616980-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926071076/tm2616980-1_4seq1.xml","form_type":"4"}},{"id":747333,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-06T00:00:14.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":5500,"price":78.71,"value":432905.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."}],"balance_after":205648,"source":{"system":"sec-edgar","filing":"0001104659-26-071076","document":"tm2616980-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926071076/tm2616980-1_4seq1.xml","form_type":"4"}},{"id":747332,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-06T00:00:14.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":211148,"source":{"system":"sec-edgar","filing":"0001104659-26-071076","document":"tm2616980-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926071076/tm2616980-1_4seq1.xml","form_type":"4"}},{"id":753113,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-03T20:52:47.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":9136,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from June 2, 2026."}],"balance_after":9136,"derivative":{"exercise_price":55.23,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":9136},"source":{"system":"sec-edgar","filing":"0000907654-26-000052","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000052/form4.xml","form_type":"4"}},{"id":766804,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-22T20:54:18.000Z","date":"2026-05-21","kind":"exercise","planned":true,"acquired":false,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests as to 1/12 of the shares underlying the option monthly from June 2, 2025."}],"balance_after":5833,"derivative":{"exercise_price":11.77,"expiration_date":"2035-06-01","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0000907654-26-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000043/form4.xml","form_type":"4"}},{"id":766803,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2026-05-22T20:54:18.000Z","date":"2026-05-21","kind":"exercise","planned":true,"acquired":false,"shares":11904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests as to 25% of the shares underlying the option on April 3, 2025, and as to 1/48 of the shares underlying the option monthly thereafter."}],"balance_after":10952,"derivative":{"exercise_price":7.8,"expiration_date":"2034-07-14","underlying":"Common Stock","underlying_shares":11904},"source":{"system":"sec-edgar","filing":"0000907654-26-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000043/form4.xml","form_type":"4"}},{"id":766802,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-22T20:54:18.000Z","date":"2026-05-21","kind":"exercise","planned":true,"acquired":false,"shares":38689,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 25% of the shares underlying the option on March 1, 2025, and as to 1/48 of the shares underlying the option monthly thereafter."}],"balance_after":32737,"derivative":{"exercise_price":6.84,"expiration_date":"2034-05-06","underlying":"Common Stock","underlying_shares":38689},"source":{"system":"sec-edgar","filing":"0000907654-26-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000043/form4.xml","form_type":"4"}},{"id":766801,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T20:54:18.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":13235,"price":59.9669,"value":793661.9215,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.71 to $60.31, inclusive."}],"balance_after":73743,"source":{"system":"sec-edgar","filing":"0000907654-26-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000043/form4.xml","form_type":"4"}},{"id":766800,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T20:54:18.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":53447,"price":59.1036,"value":3158910.1092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.71 to $59.70, inclusive."}],"balance_after":86978,"source":{"system":"sec-edgar","filing":"0000907654-26-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000043/form4.xml","form_type":"4"}},{"id":766799,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T20:54:18.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":38318,"price":58.4267,"value":2238794.2906,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.71 to $58.70, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."}],"balance_after":140425,"source":{"system":"sec-edgar","filing":"0000907654-26-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000043/form4.xml","form_type":"4"}},{"id":766798,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T20:54:18.000Z","date":"2026-05-21","kind":"exercise","planned":true,"acquired":true,"shares":11667,"price":11.77,"value":137320.59,"ownership":{"direct":true},"balance_after":178743,"source":{"system":"sec-edgar","filing":"0000907654-26-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000043/form4.xml","form_type":"4"}},{"id":766797,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T20:54:18.000Z","date":"2026-05-21","kind":"exercise","planned":true,"acquired":true,"shares":11904,"price":7.8,"value":92851.2,"ownership":{"direct":true},"balance_after":167076,"source":{"system":"sec-edgar","filing":"0000907654-26-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000043/form4.xml","form_type":"4"}},{"id":766796,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T20:54:18.000Z","date":"2026-05-21","kind":"exercise","planned":true,"acquired":true,"shares":38689,"price":6.84,"value":264632.76,"ownership":{"direct":true},"balance_after":155172,"source":{"system":"sec-edgar","filing":"0000907654-26-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000043/form4.xml","form_type":"4"}},{"id":786150,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-09T00:00:09.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":123040,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-058129","document":"tm2613976-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926058129/tm2613976-1_4seq1.xml","form_type":"4"}},{"id":786149,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-09T00:00:09.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":1800,"price":84.6,"value":152280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.44 to $84.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":207023,"source":{"system":"sec-edgar","filing":"0001104659-26-058129","document":"tm2613976-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926058129/tm2613976-1_4seq1.xml","form_type":"4"}},{"id":786148,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-09T00:00:09.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":3700,"price":83.92,"value":310504.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.35 to $84.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":208823,"source":{"system":"sec-edgar","filing":"0001104659-26-058129","document":"tm2613976-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926058129/tm2613976-1_4seq1.xml","form_type":"4"}},{"id":786147,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-09T00:00:09.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":212523,"source":{"system":"sec-edgar","filing":"0001104659-26-058129","document":"tm2613976-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926058129/tm2613976-1_4seq1.xml","form_type":"4"}},{"id":815181,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-04T00:00:49.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":127165,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-039709","document":"tm2611042-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926039709/tm2611042-1_4seq1.xml","form_type":"4"}},{"id":815180,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:49.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":85.89,"value":8589.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."}],"balance_after":208398,"source":{"system":"sec-edgar","filing":"0001104659-26-039709","document":"tm2611042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926039709/tm2611042-1_4seq1.xml","form_type":"4"}},{"id":815179,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:49.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":2702,"price":85.33,"value":230561.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.87 to $85.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon\nrequest, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":208498,"source":{"system":"sec-edgar","filing":"0001104659-26-039709","document":"tm2611042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926039709/tm2611042-1_4seq1.xml","form_type":"4"}},{"id":815178,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:49.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":2698,"price":84.31,"value":227468.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.87 to $84.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":211200,"source":{"system":"sec-edgar","filing":"0001104659-26-039709","document":"tm2611042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926039709/tm2611042-1_4seq1.xml","form_type":"4"}},{"id":815177,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:49.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":213898,"source":{"system":"sec-edgar","filing":"0001104659-26-039709","document":"tm2611042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926039709/tm2611042-1_4seq1.xml","form_type":"4"}},{"id":855318,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-07T01:00:10.000Z","date":"2026-03-04","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":131290,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-024831","document":"tm268128-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926024831/tm268128-1_4seq1.xml","form_type":"4"}},{"id":855317,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-07T01:00:10.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":200,"price":73.26,"value":14652.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.20 to $73.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":209773,"source":{"system":"sec-edgar","filing":"0001104659-26-024831","document":"tm268128-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926024831/tm268128-1_4seq1.xml","form_type":"4"}},{"id":855316,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-07T01:00:10.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":2075,"price":71.98,"value":149358.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.51 to $72.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":209973,"source":{"system":"sec-edgar","filing":"0001104659-26-024831","document":"tm268128-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926024831/tm268128-1_4seq1.xml","form_type":"4"}},{"id":855315,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-07T01:00:10.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":3225,"price":70.33,"value":226814.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.30 to $70.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":212048,"source":{"system":"sec-edgar","filing":"0001104659-26-024831","document":"tm268128-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926024831/tm268128-1_4seq1.xml","form_type":"4"}},{"id":855314,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-07T01:00:10.000Z","date":"2026-03-04","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":215273,"source":{"system":"sec-edgar","filing":"0001104659-26-024831","document":"tm268128-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926024831/tm268128-1_4seq1.xml","form_type":"4"}},{"id":918833,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-05T01:02:30.000Z","date":"2026-02-04","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":135415,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-010454","document":"tm265045-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926010454/tm265045-2_4seq1.xml","form_type":"4"}},{"id":918832,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:30.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":200,"price":68.94,"value":13788.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.90 to $68.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":211148,"source":{"system":"sec-edgar","filing":"0001104659-26-010454","document":"tm265045-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926010454/tm265045-2_4seq1.xml","form_type":"4"}},{"id":918831,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:30.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":100,"price":67.88,"value":6788.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.80 to $67.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":211348,"source":{"system":"sec-edgar","filing":"0001104659-26-010454","document":"tm265045-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926010454/tm265045-2_4seq1.xml","form_type":"4"}},{"id":918830,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:30.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":1299,"price":66.85,"value":86838.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.37 to $67.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":211448,"source":{"system":"sec-edgar","filing":"0001104659-26-010454","document":"tm265045-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926010454/tm265045-2_4seq1.xml","form_type":"4"}},{"id":918829,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:30.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":1420,"price":65.83,"value":93478.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.27 to $66.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":212747,"source":{"system":"sec-edgar","filing":"0001104659-26-010454","document":"tm265045-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926010454/tm265045-2_4seq1.xml","form_type":"4"}},{"id":918828,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:30.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":2481,"price":64.88,"value":160967.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.24 to $65.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":214167,"source":{"system":"sec-edgar","filing":"0001104659-26-010454","document":"tm265045-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926010454/tm265045-2_4seq1.xml","form_type":"4"}},{"id":918827,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:30.000Z","date":"2026-02-04","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":216648,"source":{"system":"sec-edgar","filing":"0001104659-26-010454","document":"tm265045-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926010454/tm265045-2_4seq1.xml","form_type":"4"}},{"id":932709,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T21:31:31.000Z","date":"2026-01-23","kind":"other","planned":false,"acquired":true,"shares":116483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the pro-rata distribution of shares of common stock for no consideration from a limited liability company in which the Reporting Person is a member."}],"balance_after":116483,"source":{"system":"sec-edgar","filing":"0000907654-26-000013","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000013/form4.xml","form_type":"4"}},{"id":941763,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-10T01:00:26.000Z","date":"2026-01-07","kind":"exercise","planned":true,"acquired":false,"shares":14025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":139540,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":14025},"source":{"system":"sec-edgar","filing":"0001104659-26-002574","document":"tm262641-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926002574/tm262641-1_4seq1.xml","form_type":"4"}},{"id":941762,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-10T01:00:26.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":100,"price":80.06,"value":8006.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."}],"balance_after":212523,"source":{"system":"sec-edgar","filing":"0001104659-26-002574","document":"tm262641-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926002574/tm262641-1_4seq1.xml","form_type":"4"}},{"id":941761,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-10T01:00:26.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":826,"price":79.04,"value":65287.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.70 to $79.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":212623,"source":{"system":"sec-edgar","filing":"0001104659-26-002574","document":"tm262641-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926002574/tm262641-1_4seq1.xml","form_type":"4"}},{"id":941760,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-10T01:00:26.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":14820,"price":77.9,"value":1154478.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.45 to $78.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":213449,"source":{"system":"sec-edgar","filing":"0001104659-26-002574","document":"tm262641-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926002574/tm262641-1_4seq1.xml","form_type":"4"}},{"id":941759,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-10T01:00:26.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":2954,"price":77.13,"value":227842.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $76.44 to $77.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":228269,"source":{"system":"sec-edgar","filing":"0001104659-26-002574","document":"tm262641-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926002574/tm262641-1_4seq1.xml","form_type":"4"}},{"id":941758,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-10T01:00:26.000Z","date":"2026-01-07","kind":"exercise","planned":true,"acquired":true,"shares":14025,"price":22.86,"value":320611.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Due to an administrative error, the amount reported in Column 5 on the reporting person's Form 4 filed on October 3, 2025 was overstated by 53,910 shares. As a result, the beneficial ownership totals reported in the reporting person's Forms 4 filed after October 3, 2025 were each overstated by 53,910 shares. This Form 4 reflects the correct amount of common stock beneficially owned by the reporting person."}],"balance_after":231223,"source":{"system":"sec-edgar","filing":"0001104659-26-002574","document":"tm262641-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926002574/tm262641-1_4seq1.xml","form_type":"4"}},{"id":945412,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:03:32.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":83690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 83,690 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":83690,"derivative":{"exercise_price":75.78,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":83690},"source":{"system":"sec-edgar","filing":"0001104659-26-001485","document":"tm261906-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926001485/tm261906-2_4seq1.xml","form_type":"4"}},{"id":978586,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-06T01:03:48.000Z","date":"2025-12-04","kind":"sale","planned":true,"acquired":false,"shares":10900,"price":75,"value":817500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.00 to $75.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":271108,"source":{"system":"sec-edgar","filing":"0001104659-25-118986","document":"tm2532835-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925118986/tm2532835-3_4seq1.xml","form_type":"4"}},{"id":1004504,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-08T01:00:14.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":false,"shares":8060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":153565,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":8060},"source":{"system":"sec-edgar","filing":"0001104659-25-108652","document":"tm2530515-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925108652/tm2530515-1_4seq1.xml","form_type":"4"}},{"id":1004503,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-08T01:00:14.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":678,"price":56.51,"value":38313.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.31 to $56.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":282008,"source":{"system":"sec-edgar","filing":"0001104659-25-108652","document":"tm2530515-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925108652/tm2530515-1_4seq1.xml","form_type":"4"}},{"id":1004502,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-08T01:00:14.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":5607,"price":55.58,"value":311637.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.25 to $56.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":282686,"source":{"system":"sec-edgar","filing":"0001104659-25-108652","document":"tm2530515-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925108652/tm2530515-1_4seq1.xml","form_type":"4"}},{"id":1004501,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-08T01:00:14.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":54.83,"value":120626.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.24 to $55.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":288293,"source":{"system":"sec-edgar","filing":"0001104659-25-108652","document":"tm2530515-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925108652/tm2530515-1_4seq1.xml","form_type":"4"}},{"id":1004500,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-08T01:00:14.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":2300,"price":53.62,"value":123326.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.16 to $53.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":290493,"source":{"system":"sec-edgar","filing":"0001104659-25-108652","document":"tm2530515-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925108652/tm2530515-1_4seq1.xml","form_type":"4"}},{"id":1004499,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-08T01:00:14.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":true,"shares":8060,"price":22.86,"value":184251.6,"ownership":{"direct":true},"balance_after":292793,"source":{"system":"sec-edgar","filing":"0001104659-25-108652","document":"tm2530515-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925108652/tm2530515-1_4seq1.xml","form_type":"4"}},{"id":1023880,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-04T00:00:21.000Z","date":"2025-10-01","kind":"exercise","planned":true,"acquired":false,"shares":2385,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":161625,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":2385},"source":{"system":"sec-edgar","filing":"0001104659-25-096792","document":"tm2527919-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925096792/tm2527919-1_4seq1.xml","form_type":"4"}},{"id":1023879,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-10-04T00:00:21.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":5110,"price":39.8,"value":203378.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.33 to $40.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":284733,"source":{"system":"sec-edgar","filing":"0001104659-25-096792","document":"tm2527919-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925096792/tm2527919-1_4seq1.xml","form_type":"4"}},{"id":1023878,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-10-04T00:00:21.000Z","date":"2025-10-01","kind":"exercise","planned":true,"acquired":true,"shares":2385,"price":22.86,"value":54521.1,"ownership":{"direct":true},"balance_after":289843,"source":{"system":"sec-edgar","filing":"0001104659-25-096792","document":"tm2527919-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925096792/tm2527919-1_4seq1.xml","form_type":"4"}},{"id":1046619,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-09-06T00:00:11.000Z","date":"2025-09-03","kind":"sale","planned":true,"acquired":false,"shares":190,"price":38.55,"value":7324.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.54 to $38.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":233548,"source":{"system":"sec-edgar","filing":"0001104659-25-087939","document":"tm2525198-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925087939/tm2525198-1_4seq1.xml","form_type":"4"}},{"id":1046618,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-09-06T00:00:11.000Z","date":"2025-09-03","kind":"sale","planned":true,"acquired":false,"shares":2535,"price":37.82,"value":95873.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.39 to $38.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":233738,"source":{"system":"sec-edgar","filing":"0001104659-25-087939","document":"tm2525198-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925087939/tm2525198-1_4seq1.xml","form_type":"4"}},{"id":1070998,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-09T00:00:15.000Z","date":"2025-08-06","kind":"sale","planned":true,"acquired":false,"shares":2725,"price":37.78,"value":102950.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."}],"balance_after":236273,"source":{"system":"sec-edgar","filing":"0001104659-25-075801","document":"tm2522902-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925075801/tm2522902-1_4seq1.xml","form_type":"4"}},{"id":1091676,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-04T00:00:07.000Z","date":"2025-07-02","kind":"exercise","planned":true,"acquired":false,"shares":7365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":164010,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":7365},"source":{"system":"sec-edgar","filing":"0001104659-25-065888","document":"tm2519824-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925065888/tm2519824-1_4seq1.xml","form_type":"4"}},{"id":1091675,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-07-04T00:00:07.000Z","date":"2025-07-02","kind":"sale","planned":true,"acquired":false,"shares":746,"price":46.26,"value":34509.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.16 to $46.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":238998,"source":{"system":"sec-edgar","filing":"0001104659-25-065888","document":"tm2519824-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925065888/tm2519824-1_4seq1.xml","form_type":"4"}},{"id":1091674,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-07-04T00:00:07.000Z","date":"2025-07-02","kind":"sale","planned":true,"acquired":false,"shares":2935,"price":45.49,"value":133513.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.14 to $46.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":239744,"source":{"system":"sec-edgar","filing":"0001104659-25-065888","document":"tm2519824-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925065888/tm2519824-1_4seq1.xml","form_type":"4"}},{"id":1091673,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-07-04T00:00:07.000Z","date":"2025-07-02","kind":"sale","planned":true,"acquired":false,"shares":6409,"price":44.77,"value":286930.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.12 to $45.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":242679,"source":{"system":"sec-edgar","filing":"0001104659-25-065888","document":"tm2519824-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925065888/tm2519824-1_4seq1.xml","form_type":"4"}},{"id":1091672,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-07-04T00:00:07.000Z","date":"2025-07-02","kind":"exercise","planned":true,"acquired":true,"shares":7365,"price":22.86,"value":168363.9,"ownership":{"direct":true},"balance_after":249088,"source":{"system":"sec-edgar","filing":"0001104659-25-065888","document":"tm2519824-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925065888/tm2519824-1_4seq1.xml","form_type":"4"}},{"id":1119073,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-06-07T00:01:21.000Z","date":"2025-06-04","kind":"sale","planned":true,"acquired":false,"shares":2725,"price":36.96,"value":100716.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."}],"balance_after":241723,"source":{"system":"sec-edgar","filing":"0001104659-25-057468","document":"tm2517306-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925057468/tm2517306-1_4seq1.xml","form_type":"4"}},{"id":1126285,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-03T20:13:39.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from June 2, 2025."}],"balance_after":17500,"derivative":{"exercise_price":11.77,"expiration_date":"2035-06-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001062993-25-010825","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000106299325010825/form4.xml","form_type":"4"}},{"id":1153213,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-05-10T00:01:12.000Z","date":"2025-05-07","kind":"sale","planned":true,"acquired":false,"shares":2725,"price":35.75,"value":97418.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.23 to $36.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":244448,"source":{"system":"sec-edgar","filing":"0001104659-25-046896","document":"tm2514565-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925046896/tm2514565-1_4seq1.xml","form_type":"4"}},{"id":1177318,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-04-05T00:01:18.000Z","date":"2025-04-02","kind":"sale","planned":true,"acquired":false,"shares":889,"price":37.59,"value":33417.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.34 to $37.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":247173,"source":{"system":"sec-edgar","filing":"0001104659-25-032308","document":"tm2511489-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925032308/tm2511489-1_4seq1.xml","form_type":"4"}},{"id":1177317,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-04-05T00:01:18.000Z","date":"2025-04-02","kind":"sale","planned":true,"acquired":false,"shares":500,"price":37.03,"value":18515.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.32 to $37.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":248062,"source":{"system":"sec-edgar","filing":"0001104659-25-032308","document":"tm2511489-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925032308/tm2511489-1_4seq1.xml","form_type":"4"}},{"id":1177316,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-04-05T00:01:18.000Z","date":"2025-04-02","kind":"sale","planned":true,"acquired":false,"shares":2471,"price":35.56,"value":87868.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.09 to $36.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":248562,"source":{"system":"sec-edgar","filing":"0001104659-25-032308","document":"tm2511489-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925032308/tm2511489-1_4seq1.xml","form_type":"4"}},{"id":1216729,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-08T01:02:04.000Z","date":"2025-03-05","kind":"sale","planned":true,"acquired":false,"shares":1590,"price":30.48,"value":48463.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."}],"balance_after":251033,"source":{"system":"sec-edgar","filing":"0001104659-25-021862","document":"tm258443-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925021862/tm258443-1_4seq1.xml","form_type":"4"}},{"id":1278233,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-08T01:02:15.000Z","date":"2025-02-05","kind":"exercise","planned":true,"acquired":false,"shares":795,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":171375,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":795},"source":{"system":"sec-edgar","filing":"0001104659-25-010645","document":"tm255633-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925010645/tm255633-2_4seq1.xml","form_type":"4"}},{"id":1278232,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-08T01:02:15.000Z","date":"2025-02-05","kind":"sale","planned":true,"acquired":false,"shares":3520,"price":40.69,"value":143228.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.42 to $41.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":252623,"source":{"system":"sec-edgar","filing":"0001104659-25-010645","document":"tm255633-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925010645/tm255633-2_4seq1.xml","form_type":"4"}},{"id":1278231,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-08T01:02:15.000Z","date":"2025-02-05","kind":"exercise","planned":true,"acquired":true,"shares":795,"price":22.86,"value":18173.7,"ownership":{"direct":true},"balance_after":256143,"source":{"system":"sec-edgar","filing":"0001104659-25-010645","document":"tm255633-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925010645/tm255633-2_4seq1.xml","form_type":"4"}},{"id":1313090,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-04T01:00:10.000Z","date":"2025-01-02","kind":"exercise","planned":true,"acquired":false,"shares":1360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":172170,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":1360},"source":{"system":"sec-edgar","filing":"0001104659-25-000956","document":"tm251928-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925000956/tm251928-1_4seq1.xml","form_type":"4"}},{"id":1313089,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-04T01:00:10.000Z","date":"2025-01-02","kind":"sale","planned":true,"acquired":false,"shares":100,"price":47.92,"value":4792.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."}],"balance_after":255348,"source":{"system":"sec-edgar","filing":"0001104659-25-000956","document":"tm251928-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925000956/tm251928-1_4seq1.xml","form_type":"4"}},{"id":1313088,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-04T01:00:10.000Z","date":"2025-01-02","kind":"sale","planned":true,"acquired":false,"shares":2486,"price":47.21,"value":117364.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.88 to $47.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":255448,"source":{"system":"sec-edgar","filing":"0001104659-25-000956","document":"tm251928-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925000956/tm251928-1_4seq1.xml","form_type":"4"}},{"id":1313087,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-04T01:00:10.000Z","date":"2025-01-02","kind":"sale","planned":true,"acquired":false,"shares":1499,"price":46.42,"value":69583.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.87 to $46.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":257934,"source":{"system":"sec-edgar","filing":"0001104659-25-000956","document":"tm251928-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925000956/tm251928-1_4seq1.xml","form_type":"4"}},{"id":1313086,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-04T01:00:10.000Z","date":"2025-01-02","kind":"exercise","planned":true,"acquired":true,"shares":1360,"price":22.86,"value":31089.6,"ownership":{"direct":true},"balance_after":259433,"source":{"system":"sec-edgar","filing":"0001104659-25-000956","document":"tm251928-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925000956/tm251928-1_4seq1.xml","form_type":"4"}},{"id":1331801,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-14T01:01:11.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":false,"shares":1815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":173530,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":1815},"source":{"system":"sec-edgar","filing":"0001104659-24-128559","document":"tm2430955-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924128559/tm2430955-1_4seq1.xml","form_type":"4"}},{"id":1331800,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-12-14T01:01:11.000Z","date":"2024-12-11","kind":"sale","planned":true,"acquired":false,"shares":455,"price":50,"value":22750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."}],"balance_after":258073,"source":{"system":"sec-edgar","filing":"0001104659-24-128559","document":"tm2430955-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924128559/tm2430955-1_4seq1.xml","form_type":"4"}},{"id":1331799,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-12-14T01:01:11.000Z","date":"2024-12-11","kind":"sale","planned":true,"acquired":false,"shares":4085,"price":48.62,"value":198612.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024."}],"balance_after":258528,"source":{"system":"sec-edgar","filing":"0001104659-24-128559","document":"tm2430955-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924128559/tm2430955-1_4seq1.xml","form_type":"4"}},{"id":1331798,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-12-14T01:01:11.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":true,"shares":1815,"price":22.86,"value":41490.9,"ownership":{"direct":true},"balance_after":262613,"source":{"system":"sec-edgar","filing":"0001104659-24-128559","document":"tm2430955-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924128559/tm2430955-1_4seq1.xml","form_type":"4"}},{"id":1334957,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-12T01:01:14.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":124962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 124,962 shares of the Issuer's common stock, and will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":124962,"derivative":{"exercise_price":49.07,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":124962},"source":{"system":"sec-edgar","filing":"0001104659-24-127704","document":"tm2430773-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924127704/tm2430773-1_4seq1.xml","form_type":"4"}},{"id":1340032,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-12-07T01:02:06.000Z","date":"2024-12-04","kind":"sale","planned":true,"acquired":false,"shares":6665,"price":46.07,"value":307056.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023."}],"balance_after":260798,"source":{"system":"sec-edgar","filing":"0001104659-24-126395","document":"tm2430233-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924126395/tm2430233-1_4seq1.xml","form_type":"4"}},{"id":1370733,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-09T01:02:19.000Z","date":"2024-11-06","kind":"sale","planned":true,"acquired":false,"shares":1339,"price":59.96,"value":80286.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.55 to $60.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":267463,"source":{"system":"sec-edgar","filing":"0001104659-24-116027","document":"tm2427837-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924116027/tm2427837-1_4seq1.xml","form_type":"4"}},{"id":1370732,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-09T01:02:19.000Z","date":"2024-11-06","kind":"sale","planned":true,"acquired":false,"shares":5326,"price":58.91,"value":313754.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.50 to $59.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":268802,"source":{"system":"sec-edgar","filing":"0001104659-24-116027","document":"tm2427837-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924116027/tm2427837-1_4seq1.xml","form_type":"4"}},{"id":1390531,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-10-05T00:02:03.000Z","date":"2024-10-02","kind":"sale","planned":true,"acquired":false,"shares":925,"price":56.86,"value":52595.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.64 to $57.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":274128,"source":{"system":"sec-edgar","filing":"0001104659-24-106367","document":"tm2425574-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924106367/tm2425574-1_4seq1.xml","form_type":"4"}},{"id":1390530,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-10-05T00:02:03.000Z","date":"2024-10-02","kind":"sale","planned":true,"acquired":false,"shares":5740,"price":56.16,"value":322358.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.62 to $56.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":275053,"source":{"system":"sec-edgar","filing":"0001104659-24-106367","document":"tm2425574-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924106367/tm2425574-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2024-10-05T00:02:03.000000Z,1390530"}